Transdifferentiation toward an aggressive small-cell neuroendocrine cancer (SCNC) phenotype occurs in response to targeted therapies, for example, in resistance to epidermal growth factor receptor (EGFR) kinase inhibitors in lung adenocarcinomas [35]. Here, EGFR is linked to lung adenocarcinoma.